NYSAM 2011 Case Presentation

Slides:



Advertisements
Similar presentations
Director Peter Delany, Ph
Advertisements

TRI science addiction Lost Opportunity? SBI for Substance Abuse In ERs and Trauma Centers Academy Health Mady Chalk, Ph.D. Treatment Research Institute.
MEDICATION ASSISTED ADDICTION TREATMENT: APPROPRIATE USE DAS Quarterly Provider Meeting Louis E. Baxter, Sr., M.D., FASAM Medical Director-DAS President.
Risk and Opioid Therapy Russell K. Portenoy MD Chairman Department of Pain Medicine and Palliative Care.
Office-Based Opioid Therapy: Methadone/Buprenorphine Nexus
Palliative Sedation Pam Mansfield, MD, CCFP October 2, 2009.
Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
The Third International Theraplay Conference 2007 Chicago Ulrike Franke and Herbert H.G. Wettig Presenter: Ulrike Franke, Cert. Theraplay Trainer - Supervisor.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
13 Principles of Effective Addictions Treatment
1 Managing Substance Use Disorders (SUDS) as a Chronic Condition Michael L. Dennis, Ph.D. Chestnut Health Systems 720 W. Chestnut, Bloomington, IL 61701,
Click the arrows to advance forward and backward. Click the Next link below to advance to the assessment. The A B C & D’s of Suicide Assessment and Clinical.
Client satisfaction and perceptions of treatments in the North American Opiate Medication Initiative Kirsten Marchand, MSc Candidate at UBC SPPH Canadian.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
What is the evidence for time limiting addiction treatment?
DBHDS Vision: A life of possibilities for all Virginians Treatment for Opioid Addiction Public Community Treatment in Virginia Virginia Heroin and Prescription.
Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice Erin Inglis, MD a, Jessie Burch, PharmD b, Nida Awadallah, MD c,,
Aberrant Drug-taking Behaviors: What Do We Know?
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Identifying and Addressing Aberrant Medication Use Behaviors.
Pain and Chemical Dependency Not an “Either – Or” proposition Douglas Gourlay, MD, FRCPC, FASAM Wasser Pain Centre, Toronto ON.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Sublingual Buprenorphine and Pain
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Substance Abuse Issues in Chronic Pain Management Steven D. Passik, PhD Director, Oncology Symptom Control and Research Community Cancer Care, Inc. Indianapolis,
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
® Introduction Substance Abuse and Use of Opioids for Low Back Pain Nabil Aounallah, Sunand Kallumadanda, MD, Sandra Burge, PhD The University of Texas.
Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Aberrant Drug-taking Behaviors in Medically Ill Pain Patients Steven D. Passik, PhD Director,
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Concerns About Addiction: Bringing Clarity to Confusion about Addiction Terminology Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist.
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
For Pain or Not for Pain: Methadone Madness
Medications for Pain: What You Need to Know for Treatment in Workers’ Compensation Suzanne Novak, MD, PhD 5/17/07.
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Opioid Use in Workers’ Compensation Suzanne Novak, MD, PhD November 2008.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.
Use of Opioids fro Chronic Pain in Primary Care Norman Wetterau MD
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Ph: Disclaimer: Information on this page is not a substitute for medical consultation.
Efficacious Physician-Patient Relationships Or Physician, Therapist and Patient Relationships Elliot S. Cohen, M. D. M. L. Grabill, M.Ed. PsychiatristLicensed.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
Addiction and dependence Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Prevention, Identification and Treatment of Opioid Use Disorders: A Personal Perspective Leah Bauer, MD Medical Director, Addiction Resource Center, Mid.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Dr. Rupak Sethuraman. SPECIFIC LEARNING OBJECTIVES Various management techniques of orofacial pain Management of common orofacial pain disorders.
Chronic Pain Management Harald Lausen, DO, MA FCM Clerkship SIU School of Medicine.
The Science of Addiction. Homelessness Crime Violence Homelessness Crime Violence Neurotoxicity AIDS, Cancer Mental illness Neurotoxicity AIDS, Cancer.
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Current Concepts in Pain Management
Larry Halverson, MD Gabrielle Curtis, MD Cox FMR Springfield MO
Opioid Prescribing & Monitoring
Substance-Related and Addictive Disorders
Treatments for Addiction
Assessing Opioid Use Disorder, part 1
Tapering and Discontinuing Chronic Opioid Therapy
Presentation transcript:

NYSAM 2011 Case Presentation Edwin A. Salsitz, M.D. FASAM Beth Israel Medical Center New York City

Physician Clinical Support System PCSS… answers questions about opioids, including methadone, for treatment of chronic pain answers questions about use of buprenorphine for treatment of opioid dependence

Physician Clinical Support System PCSS… is free, for interested physicians and staff is supported by SAMHSA through the Center for Substance Abuse Treatment (CSAT) and administered by the American Society of Addiction Medicine (ASAM)

Physician Clinical Support System Ask a clinical question… get a response from an expert PCSS mentor on line by email PCSSproject@asam.org by phone 877-630-8812 From www.PCSSmentor.org... download clinical tools, helpful forms and concise guidance's (like FAQs) on specific questions

ADDICTION/PAIN TREATMENT “All Treatments Work For Some People/Patients” “No One Treatment Works for All People/Patients” Alan I. Leshner, Ph.D Former Director NIDA

CT 2010 Case Presentation 54 y.o. ♀ evaluated on 6/19/09 Headaches major medical problem ? Paternal uncle—EtOH Lives with husband, has 2 adult stepchildren Upper level executive in marketing, 250K Through H.S. no drugs or EtOH

CT 2010 Case Boyfriend 1st year of college introduced to heroin IN 1st use may have led to gang rape? Uncontrollable crying over story 1st “migraine” around this time, frequent & severe “nervous breakdown” after boyfriend ends relationship in 2nd year college Heroin INIV x 2yrsillicit methadoneTC Abstinent age 25

CT 2010 Case Migraines lessened in 30’s and 40’s  frequency and severity post-menopause Opioids X 4 years—oxyCR & oxyIR Nationally known HA clinic—weaned off opioids 2 yrs ago—severe HAsopioids(1 mo.) Neuro and Pain Specialist—ran out of meds 1 week early? Inpatient “detox”--?work Current meds. Oxy CR 30mg tid OxyIR 5mg qid(NSAID, ondansetron, prednisone, venlafaxine, topiramate)

CT 2010 Case Age 17—appendectomy—1st opioid— “felt good,” “took away my insecurities” Subsequent heroin--- “energized” Sobbing and Crying at mention of mother who died 9 mos ago at age 93 Felt she was a terrible disappointment to mother Saw therapist on and off for many years—currently not in psychotherapy

Diagnosis and Plan After Initial Consultation Opioid Physical Dependence Pain Paradigm Husband to Dispense Opioids Attempt to taper opioids Rx Oxy CR 30mg—attempt bid One week later 1.Oxy CR bid 2. D/C venlafaxine, start duloxetine 3. Oxy IR 5 q6h prn

3 Weeks later Headaches have markedly increased while on vacation—husband not in agreement on chronic opioid paradigm Neurologist adds gabapentin 300mg tid and topiramate(now 100mg.qd) Continued attempts to taper opioids not successful

4 Weeks Later Husband no longer coming in with patient Headaches daily—making work and home difficult After long discussion, OXY CR d/c’d and methadone low dose started and titrated upwards

After 7 months Stable methadone dose 30mg tid Infrequent short acting opioids Significant improvement in headache frequency, severity, Improved function at work Stopped therapy, and refuses new therapy Marital issues difficult to discuss All urines, pill counts, appts., etc reveal no problematic behavior Overall patient rating 93(as of 4/13/10)

April 2010Present June 2010—2 Rxs given for methadone October 2010---Short Acting Opioids D/C’d October 2010---Methadone  30mg bid Headaches present, but  intensity/frequency Stigma issue around methadone continues Marital issue, no psychosocial Random urines negative

41(59%) Responders by 50% in SHI—freq x duration severe headache/week NEUROLOGY 2004;62:1687-1694 160 enrolled 70 remained on daily scheduled opioids X 4 yrs 74% LA, 26% SA 41(59%) Responders by 50% in SHI—freq x duration severe headache/week

Figure 1. Medical record versus visual analog scale: mean percentage improvement in year 3 or 4 of daily scheduled opioids (year 4 for patients in program for 4 years or more)‏ Saper, J. R. et al. Neurology 2004;62:1687-1694

Dose Violation most common Most problems not “severe” Figure 2. Problem drug-related behavior: patients with any incident of problem opioid behavior over 4 years of daily scheduled opioids Saper, J. R. et al. Neurology 2004;62:1687-1694 Dose Violation most common Most problems not “severe”

OPIOIDS ? Endorphin Deficiency U B E T Chronic Pain Addiction Somatic Sxs Hedonic Tone OPIOIDS ? Endorphin Deficiency Anti-Depressants Anti-Convulsants Mood Stabilizers Pain Medicine Prescriptions Pharmacies Legitimate Addiction Treatment Methadone Clinics Regulations Stigma Buprenorphine

*Anterior Cingulate Gyrus

MesoLimbic Dopaminergic Circuit Pleasure/Reward Center Acc VTA Amphetamine Cocaine Opiates Cannabinoids Phencyclidine Ketamine HIPP GLU FCX AMYG CRF GLU 5HT GABA OPIOID OPIOID ENK GABA GABA VP DYN 5HT OFT DA BNST GABA NE ABN LC Opiates PAG NE HYPOTHAL END LAT-TEG To dorsal horn Opiates Ethanol Barbiturates Benzodiazepines Nicotine Cannabinoids 5HT ICSS Raphé MesoLimbic Dopaminergic Circuit Pleasure/Reward Center H2O, Food, Sex, Parenting, Socializing RETIC

HCC=Healthcare for Communities 1998, 2001

Association of common mental disorders in 1998 with regular prescription opioid use in 2001: unadjusted odds ratios with 95% confidence intervals Sullivan, M. D. et al. Arch Intern Med 2006;166:2087-2093. Non-Cancer Pain Copyright restrictions may apply.

Journal of Addictive Diseases, Vol.27(3) 2008

Journal of Addictive Diseases, Vol.27(3) 2008

Problematic (Aberrant) Behaviors Probably more predictive Selling prescription drugs Prescription forgery Stealing or borrowing another patient’s drugs Injecting oral formulation Obtaining prescription drugs from non-medical sources Concurrent abuse of related illicit drugs Multiple unsanctioned dose escalations Recurrent prescription losses Probably less predictive Aggressive complaining about need for higher doses Drug hoarding during periods of reduced symptoms Requesting specific drugs Acquisition of similar drugs from other medical sources Unsanctioned dose escalation 1-2 times Unapproved use of the drug to treat another symptom Reporting psychic effects not intended by the clinician Passik and Portenoy, 1998

The ORT Form-Opioid Risk Tool Mark each box that applies 1. Family history of substance abuse Female Male Alcohol [ ] [ ] Illegal drugs [ ] [ ] Prescription drugs [ ] [ ] 2. Personal history of substance abuse Alcohol [ ] [ ] 3. Age (mark box if 16-45) [ ] [ ] 4. History of preadolescent sexual abuse [ ] [ ] 5. Psychological disease Attention deficit disorder, obsessive- compulsive disorder, bipolar, schizophrenia [ ] [ ] Depression [ ] [ ] 1 2 4 3 5 Patients are asked to identify their age; history of preadolescent sexual abuse; family and personal history of substance abuse, including alcohol, illegal drug, or prescription drug abuse; and psychological diseases such as attention deficit disorder, obsessive-compulsive disorder, bipolar disorder, schizophrenia, or depression. The probability of opioid abuse increases with the number of positive responses. Responses to each question are weighted differently based on gender and risk factor. Each risk factor is assigned a point value comparative to other risk factors. Courtesy of Lynn Webster, M.D.

Validation Study Results Total score risk category   Low risk: 0–3   Moderate risk: 4–7   High risk: ≥ 8 Validation Study Results ORT Total Score Risk Category 100 90.9 80 60 Aberrant Behavior Displayed (%) 40 28 The validation study of the ORT showed a strong relationship of the link between the total score risk category and observed aberrant behavior. For those patients in the low risk category, “unlikely to abuse opioids”, only 5.6% displayed an aberrant behavior. For those patients in the moderate risk category, “as likely to abuse opioids as not to abuse opioids”, 28% displayed aberrant behaviors. For those patients in the high risk category, “likely to abuse opioids”, 90.9% displayed aberrant behavior. The ORT displayed excellent discrimination for both sensitivity and specificity and provided gender-specific positive predictive values for high risk patients of 87% to over 95%. 20 5.6 Low Moderate High Webster LR and Webster RM. Predicting aberrant behaviors in opioid-treated patients: validation of the Opioid Risk Tool. Pain Med. 2005;6:432-442. Non-Cancer Pain

Russell Portenoy, M.D.

“…as we know, there are known knowns, there are things we know we know “…as we know, there are known knowns, there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns – the ones we don’t know we don’t know.” – Donald Rumsfeld

“MORPHINE IS GOD’S OWN MEDICINE” Sir William Osler

ADDICTION/PAIN TREATMENT “All Treatments Work For Some People/Patients” “No One Treatment Works for All People/Patients” Alan I. Leshner, Ph.D Former Director NIDA

SUPPORT ASAM!!